Abstract Library

#64 Sustained response to anti IGFR-1R monoclonal antibody combined with docetaxel in a patient with metastatic adrenocortical carcinoma

Introduction: Adrenocortical carcinoma (ACC) is a rare neoplasm with poor prognosis. Treatment results in advanced disease are disappointing and median survival is less than 12 months. There is no standard chemotherapy, even though mitotane and cisplatin-based regimens are frequently used with limited efficacy. In vitro data suggest that overexpressed insulin growth factor-2 (IGF-2) acting via the IGF-1 receptor (IGF-1R) is relevant for ACC and that the IGF-1R and 2R pathway is a promising target.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: De Dosso S, Saletti P, Gallerani E, Terrot T, Sessa C,

Keywords: adrenocortical carcinoma, anti IGFR-1R monoclonal antibody,